Pinned Tweet
LT position PART 1
Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE
Tech positions: In order
$AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB
Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR
Pharmdca retweeted
$SPY $QQQ $CRWV $NVDA
RUMORS OF VARA BLOWING UP 🧨
Background from GOOGLE:
VARA is that Princeton AI fund that went nuclear after launching the long/short book in early 25 Hoskin and Field, pure “transformative AI” infra/power/semis, ballooned to $20B flagship and total firm $26B by mid-year. Crushed it through June (nearly +200%) then got smoked -44% in July on the crowded unwind with Situational Awareness 👀
🍌Opinions, same names as Leopold everywhere: CRWV, BE, IREN, etc., supposedly since then their Assets Under Management AUM has been shrinking 👎
“VARA blew up” rumor is just the next layer of an already stressed AI trade🤦♂️. These guys were piled into the exact same stuff. When one big levered long has to degross the names get dumped whether the demand story changed or not. Honestly the price action looked like some fund got carted out, now there’s smoke 💨 where there was fire 🔥
I LIKE BLOWUPS ON DUMB FUNDS IT IFTEN MARKS LOCAL BOTTOMS!!! 🤔
$CRWV is the poster child, getting absolutely crushed down near the $60 lows with volume exploding. That looks like forced selling flushing out the weak hands after the prior base failed. Banana325SMA and the longer averages still overhead for now, RSI deeply oversold, MACD ugly but stretched. Classic “everyone watching, nobody in” setup 👀
Same vibe across the AI infrastructure complex as well. July was our earlier preview. Demand hasn’t disappeared hyperscalers still can’t get enough capacity and the buildout continues. This is positioning pain, not a thesis break.
Technicals need to hold these lows and start reclaiming structure. If the forced selling exhausts, first magnet is back toward Tuesday’s prior zones. Lose the lows on heavy volume and more pain until real buyers step up. AI thesis is still intact!!
Not financial advice!
Much love! 💜🍌🍌🍌
Here's my list of people I recommend following on X. It's a very short list, because I value signal over noise.
Tech Sector
@StockMarketNerd
@WisemanCap
@Banana3Stocks
@ripster47
@JonahLupton
@ChillBanking
@Mr_Derivatives
@wallstengine
@Chevallier145
@BlueMoonTrades
@AIStockSavvy
@mukund
@PharmDabbler
@OMillionaires
Biotech Sector
@semodough
@Mufaso7
@BiopharmIQ
@WallStSai
@Andre_AGTC
@mtheory11bio
@Quantumup1
@GilaMonstrum
@HOThomasWPhelps
@bioinvestor24
@Biohazard3737
@doepke_michel
@dsjdirect
@Explainbiotech
Pharmdca retweeted
$NBIS getting dragged down with $CRWV and all the FUD going around. We are still compute constrained and $NBIS is doing deals at $30-50M per MW, they're going to beat Q3 earnings, raise year end ARR and do at least $15B revs in 2027 which means the stock is now trading at 3x CY2027 ev/revs.
$NBIS is pulling back to an important technical level which is the 50w sma and the .618 fibs from February lows... decent chance we see a bounce in the low $160s
Very few people on X remain rational and continue to share quality insights and constructive feedback when everyone else is panicking.
Those are the people worth following. The rest are simply amplifying the noise.
Pharmdca retweeted
$CRWV - HUANG: COREWEAVE'S COST OF CAPITAL IS `ACTUALLY DECREASING'
Retail behavior when it comes to Investing.
Typical behavior during drawdowns that repeat 🔁.
1) You invest in a company believing in the market and expecting your investments to grow over time.
2) Market drops for any given reason unrelated to your investment- Fear and panic overtakes your initial confidence resulting in emotional decisions.
3) Fear kicks in and you close your investment with a loss.
4) Within a short period same investment makes a reversal and hits higher highs.
Take home lessons- Investing is a test of patience and conviction. Focus on fundamentals, understand the risks, and keep your long-term goals in perspective.
Pharmdca retweeted
$NVDA - GERMAN GOVERNMENT INTENDS TO ENTER INTO PARTNERSHIP WITH NVIDIA, HANDELSBLATT REPORTS, CITING GOVERNMENT AND INDUSTRY SOURCES
Pharmdca retweeted
$VKTX reminder just of what Ph2 showed up to 12.2% mean weight loss at 13 weeks without plateau,
with doses >15mg demonstrating statistically significant reductions vs. placebo.
$VKTX Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity - Oct 14, 2026 ir.vikingtherapeutics.com/20…
Pharmdca retweeted
$TSM Reports Q3 (NT$) Net 763.1B v 746.3Be (v 452.3B y/y), Op 876.5B v 849.6Be (v 500.7B y/y), Rev 1.49B v 1.49T prelim (TSMC)
- Op margin: 58.7% v 50.6% y/y
- Gross margin: 66.4% v 59.5% y/y v 66.5%e
- Capex: $13.8B v $9.7B y/y; YTD Capex: $40.6B v $29.4B y/y
- Management Commentary: In the third quarter, revenue increased 17.6% quarter over-quarter, as our business was supported by strong demand for our leading-edge process technologies. By technology, 2nm process technology contributed 8% of total wafer revenue in 3Q26, while 3nm, 5nm, and 7nm accounted for 33%, 28%, and 10% respectively. Advanced technologies (7nm and below) accounted for 79% of total wafer revenue. By platform, HPC and Smartphone represented 68% and 21% of net revenue respectively, while IoT, Automotive, DCE, and Others each represented 4%, 4%, 1%, and 2%. Sequentially, revenue from HPC, Smartphone, IoT, and Automotive increased 22%, 10%, 5%, and 23% respectively. DCE and Others decreased 12% and 10% respectively from 2Q26. From a geographic perspective, revenue from customers based in North America accounted for 79% of total net revenue in 3Q26, while revenue from Asia Pacific, China, Japan, and EMEA (Europe, Middle East, and Africa) accounted for 10%, 5%, 3%, and 3% of total net revenue respectively.
(More at tradethenews.com/?twtId=5533…)
Pharmdca retweeted
ANTHROPIC REVENUE JUMPS TO $16.8BN IN Q3 - FT
